Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says
MT newswire2026/10/06 15:2111:21 AM EDT, 10/06/2026 (MT Newswires) -- Johnson & Johnson's (JNJ) Innovative Medicines segment acceleration is helping overcome persistent headwinds in its MedTech business, RBC Capital Markets said in a Tuesday note. The investment firm said it expects fiscal Q3 sales to come in 1% ahead of estimates, driven by a 1.3% beat in the Innovative Medicines segment anchored by Tremfya, Icotyde, and Darzalex, while projecting EPS of $2.55, below consensus of $2.81. Analysts said the Firefly and Sail deals are not fully reflected in the consensus. Management noted about 17,000 patients were treated with Icotyde in fiscal Q3, with 60% being treatment-naive and full US insurance coverage achieved, according to the note. In MedTech, lingering competitive dynamics in electrophysiology and pulsed field ablation, along with persistent geopolitical drag, have softened the H2 recovery thesis, though procedure volumes remain intact, the firm said. The company is set to report its Q3 financial results on Oct. 13. RBC Capital Markets maintained its outperform rating on Johnson & Johnson, and raised its price target to $290 from $287. Price: 252.33, Change: -0.60, Percent Change: -0.24
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Citi: Besent May "Slash" Long-term Bond Issuance Next Month, 20-year US Treasury Issuance Could Be Directly Canceled
Citi published a research report indicating that US Treasury Secretary Scott Besant is highly likely to reduce the issuance size of long-term US Treasury bonds, and may even completely cancel the issuance of 20-year Treasury bonds.
Rising energy prices intensify inflation concerns; US Treasury yields increase again, with the 10-year rising to 5.25%.
Persistently high energy prices have intensified market concerns about the inflation outlook and reinforced investor expectations of further interest rate hikes by the Federal Reserve. After experiencing significant volatility earlier this week, U.S. Treasury yields are edging back toward recent highs.
Bastion Trading reports $78,263 SkyAI common share purchase
Bastion Trading, a 10% owner of SkyAI, bought 44,000 common shares at a weighted average price of $1.7787. Directly held common shares rose to 1,429,417 following the purchase. Indirect beneficial ownership disclosed at 2,940,075 common shares. Derivative exposure included 4,234,615 Pre-Funded Warrants, underlying common stock. Also held 5,384,615 Stapled Warrants, underlying common stock. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SkyAI Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000921895-26-002775), on October 09, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
